These findings position Fstl1 as a potential therapeutic target, particularly for diseases such as bronchopulmonary dysplasia (BPD) and COPD, by promoting healthy alveolar development and preventing structural lung degeneration. The gene discussed is FSTL1; the disease is bronchopulmonary dysplasia.